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Abstract
Despite the high level of spending on cancer medicines in Australia, consumer organisations and the pharmaceutical
industry often make claims of delayed or lack of access to new cancer medicines—claims that are frequently supported
by prominent coverage in the Australian media. These claims, while morally and psychologically compelling, tend to
ignore the complexity of medicines funding decisions. In this commentary we summarise the current situation
regarding the registration and funding of cancer medicines in Australia, elucidate the main challenges associated with
access to cancer medicines in the Australian context, and describe some of the steps that have been taken to address
these challenges.
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Background
Access to new cancer medicines is currently a highly
contentious issue in Australia. Indeed, hardly a week
goes by without lack of access to a new ‘breakthrough’
cancer medicine being highlighted in the Australian
media. Almost inevitably, existing medicines approval
and coverage processes are blamed for the problem. But
are current Australian regulatory and funding systems
really leading to ‘second-rate cancer care’ in Australia
as suggested by the Oncology Industry Taskforce
(a taskforce of 16 pharmaceutical companies) [1], the
Cancer Drugs Alliance (a multi-stakeholder organisa-
tion with close ties to the industry) [2] and some lay
media? With this question in mind, this commentary
summarises the current situation regarding the regis-
tration and funding of cancer medicines in Australia,
elucidates the main challenges associated with access
to cancer medicines in the Australian context, and
describes some of the steps that have been taken to
address these challenges.
Registration and funding of new cancer medicines in
Australia
Despite a high incidence of cancer, Australia has one of
the lowest rates of cancer mortality in the developed
world [3]. These positive outcomes are likely due to the
implementation of national cancer screening pro-
grammes, access to high quality health care services, and
universal public financing of effective cancer medicines
through the Pharmaceutical Benefits Scheme (PBS) [4].
Consistent with the first objective of the National
Medicines Policy, the PBS aims to provide ‘timely access
to the medicines that Australians need, at a cost individ-
uals and the community can afford’ [5]. In 2013-2014,
the Australian government spent AUD$1.5 billion on
cancer medicines. This represented one third of the total
cost of cancer care and 16 % of total PBS expenditure
[6]. Patients have access to these medicines for free in
hospitals, or pay a modest co-payment as out-patients
($36.90 for general and $6.00 for concessional benefi-
ciaries for a full-course of chemotherapy treatment).
Although Australia’s invests substantially in cancer
medicines, a number of studies have demonstrated
either lack of regulatory approval, or delayed approval,
of new cancer medicines in Australia compared to simi-
lar countries [7, 8]. However, the delay in regulatory
approval in Australia has mostly been explained by a
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delay in pharmaceutical companies’ applications for
registration, which were submitted on average 38 weeks
later than applications to the US Food and Drugs Ad-
ministration (FDA) and the European Medicines Agency
(EMA) [6]. Another possible contributing factor is that,
unlike the FDA and EMA, Australia’s Therapeutic Goods
Administration (TGA) does not currently have the cap-
acity to undertake expedited approvals for medicines [9].
In the US, expedited review leads to approvals on aver-
age 3.5 months earlier than standard review, but there
are serious problems with the FDA’s ability to track and re-
port on post-approval safety following expedited review
[10]. Thus the trade-off in expedited review of less
complete pre-approval data but more extensive post-
market evaluation has failed to fully live up to expectations.
Delayed funding decisions, or lack of funding of new
cancer medicines on the PBS, has also been raised as a
major concern by some consumer organisations and the
pharmaceutical industry [6]. In a study we conducted of
PBS approvals of cancer medicines, we found that 44 %
(24) of the 56 indications for new cancer medicines
approved by the TGA between 2010 and 2013 had also
received a positive funding recommendation by the
Pharmaceutical Benefit Advisory Committee (PBAC),
with an average time between the TGA authorisation
and PBAC positive recommendation of 343 days [8].
Similarly, an analysis of 182 submissions for cancer
medicines between 2005 and 2014 showed that the
overall rate of deferral or rejection was 56 % [11]. The
most common reasons for deferring or rejecting listing
of new cancer medicines on the PBS were uncertain
cost-effectiveness (38 %), unacceptable cost-effectiveness
(21 %) and uncertain effectiveness (18 %) [11]. Australia’s
PBAC is not alone in these judgments. The proportion
of positive funding decisions for cancer medicines between
1994 and 2014 in Australia was similar to rates in the
United Kingdom and Canada, two countries which also
use economic analyses to inform funding decisions [12].
Challenges associated with access to cancer medicines in
Australia
Uncertain and limited benefits of cancer medicines
While the same type of evidentiary standards are applied
to the registration and funding of cancer and non-cancer
medicines, regulators and payers face particular chal-
lenges when it comes to evaluating many cancer medi-
cines. This is largely because the quality of clinical trial
evidence on cancer medicines is generally lower than for
other therapeutic classes [13, 14]. A retrospective ana-
lysis of submissions for cancer medicines considered by
the PBAC between 2005 and 2012 found that on aver-
age, half of major submissions had significant problems
with supporting clinical evidence [15]. Although some
new cancer medicines provide important therapeutic
benefits, many new cancer medicines, especially those
marketed for advanced cancers, fail to lead to gains in
survival or lead to only minimal gains over standard care
and are sometimes associated with greater toxicity. This
makes it very difficult to demonstrate their “value” rela-
tive to alternatives [16–19].
High prices of cancer medicines
Despite the uncertain evidence of benefit for many
new cancer medicines, prices of cancer medicines
have grown dramatically in all countries over the past
15 years [20–25]. In Australia, expenditure on chemo-
therapy has been increasing faster than any other area of
health care, with an average annual growth rate of 63 %
from 2009-10 to 2013-14 [26]. This increase may be par-
tially explained by a larger number of patients being
treated, but is also likely related to the price paid per can-
cer prescription, which rose by 133 % from AUD$337 in
1999-2000 to AUD$786 in 2011-12—more than double
the increase of all other PBS medicines together [27]. A
recent survey of the prices of cancer medicines in 16
European countries, Australia and New Zealand showed
that Australian prices were generally similar to the median
prices of all countries [28]. In industry submissions to
PBAC, cancer medicines tend to have a higher cost per
quality-adjusted life-year (QALY) than non-cancer medi-
cines: 29 % of cancer medicines versus 15 % of non-cancer
medicines have a reported cost per QALY of more than
AUD 45,000 [29]. This helps to explain why cancer medi-
cines are less likely to be funded than other therapeutic
categories.
Strategies for improving access to cancer medicines
Australia’s medicines regulation and funding processes
are constantly being reviewed and revised in an effort to
improve access to safe, effective and cost-effective medi-
cines. In 2014-2015, two national reviews examined pol-
icy options for improving medicines regulatory and
funding processes in Australia: the Expert Review of
Medicines and Medical Devices Regulation [9] and the
Australian Senate’s inquiry on ‘Availability of new,
innovative and specialist cancer drugs in Australia’ [6].
We believe that three issues have emerged as being par-
ticularly important, both in reviews and in other con-
texts: 1) the need to streamline regulatory and funding
processes, 2) the need for greater consumer involvement
in decision-making and 3) the need to address the prob-
lem of high cancer drug prices.
Streamlining regulatory and funding processes
A number of steps have recently been taken in Australia
to shorten the approval-funding-listing cycle by stream-
lining administrative procedures. Since January 2011,
parallel TGA and PBAC processes have been introduced,
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thus reducing the time lag between marketing authorisa-
tion and funding approval [30]. A single entry point has
also been established for speeding applications of medi-
cines with a ‘co-dependent’ diagnostic technology (such as
a genetic test for a ‘targeted therapy’) [31]. The two re-
views mentioned above also put forward a number of new
recommendations to enhance administrative processes.
For example, they recommended that Australia should
make better use of assessments conducted by comparable
overseas regulators, and should expedite assessments in
certain circumstances which are yet to be defined.
Another innovative funding pathway that is gaining
increasing prominence in Australia and globally is the
development of managed entry agreements (MEA). Most
MEAs to date in Australia have been financial agree-
ments that involve price or volume rebates, or agree-
ments that link the continuation of funding to evidence
of benefit documented at the individual patient level
[32]. Managed access programs have been more recently
introduced in which continuation of funding is condi-
tional on the subsequent provision of favourable scien-
tific evidence of population-level efficacy. In most cases,
the manufacturer would be expected to pay a rebate to
the Government should these medicines fail to deliver
on their claimed benefits [33]. A few medicines, includ-
ing four cancer medicines (pilimumab, prembrolizumab
and trametinib for advanced melanoma and crizotinib
for non-small cell lung cancer), have been recently listed
on the PBS as part of managed access programs. How-
ever, concerns have been raised about the implementa-
tion of these programs in other countries including the
quality of the methodology of studies undertaken in ‘real
world’ settings, as well as the governance and funding of
these programs [34, 35]. It is as yet unclear whether
these programs contribute meaningfully to the evalu-
ation of the therapeutic effects of new medicines [36].
Detailed information on MEAs is not publicly available
and this lack of transparency is a major drawback be-
cause it precludes public understanding of the ways in
which decisions about initial and continued funding are
made [37, 38]. Furthermore, potential cessation of fund-
ing of medicines which are part of MEAs requires on-
going good communication for these decisions to be
understood and accepted by the public [39]. Currently,
patients who are prescribed medicines with continuation
rules are required to sign an informed consent docu-
ment. A comprehensive risk management plan may be
required for medicines which are of part of managed ac-
cess programs when discontinuation of funding at the
national level is an option [39].
Increasing consumer engagement in decision-making
The Australian Senate Committee recommended ex-
panding the role of consumers and clinicians in PBAC
assessment processes, with the objective of better align-
ing PBAC’s decisions with stakeholders’ preferences. In-
creased levels of public and patient involvement in
decision-making processes may take several forms in-
cluding higher number of consumer representatives on
decision-making committees, or more robust processes
of public consultation. These process are important in
contexts where values are likely to conflict. However,
they also raise two important issues that need to be ad-
dressed if public input is to contribute meaningfully to
decision-making. The first is how to manage conflicts of
interest, as some patient organisations rely on funding
from pharmaceutical companies. Such funding can com-
promise an organisation’s independence and its ability to
solely represent cancer patients’ interests, particularly
when PBAC is considering funding of a sponsor’s drug.
The second issue is effective management of power
imbalances, so that consumers are able to be heard and
ultimately contribute to decisions.
Transparency is also important because, although PBAC
decisions are not based on a strict utilitarian rationality
with a fixed funding threshold, they are often assumed to
be so. These assumptions—although incorrect—are able
to persist in part because the rationale and the value
judgements involved in PBAC decisions are not ad-
equately communicated to the public and patients [39].
This, in turn, is because most of the documentation sub-
mitted to the PBAC by the manufacturers and generated
during the evaluation process is considered to be commer-
cially confidential, and cannot be released publicly. While
Public Summary Documents (PSD), which summarize the
evidence basis and the reasons supporting the PBAC deci-
sions have been posted on the Australian Government’s
website since 2005 [32], PSDs are highly technical and
may be difficult for consumers to understand. Further-
more, sensitive information such as Incremental Cost
Effectiveness Ratio, financial implications, proposed prices
and details of proposed risk-share arrangements are
redacted, and PSDs are released only several months after
the PBAC decision has been made. This inadequate com-
munication may lead to misconceptions about the ration-
ale of PBAC’s decisions and misinterpretation of scientific
evidence by the patients and the media [6]. However, the
pharmaceutical industry opposes greater transparency on
the grounds of what it perceives to be ‘legitimate commer-
cial in confidence considerations’ [6].
Addressing the high prices of cancer medicines
Although the Australian Senate committee report noted
the high cost of cancer medicines, it did not comment
on the significant role of pharmaceutical companies in
delaying funding decisions by making exaggerated initial
price demands to secure the highest prices possible for
their products. We believe that this was a significant
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omission in the report and its recommendations, given
that independent experts around the world are now
warning that high priced medicines are a major threat to
the sustainability of pharmaceutical insurance schemes.
Pharmaceutical companies argue that, in the era of
personalised, or targeted, cancer therapy they must
charge more in order to recoup the cost of development
from a smaller cancer patient group. It is difficult to
evaluate these claims because lack of transparency about
the costs of drug development makes it impossible to
get reliable figures on the real cost of development of
new medicines. Industry-affiliated institutions claim that
development costs could reach US$2.56 billion per
medicine gaining approval [40], but these figures may be
grossly overestimated, and others have argued that the
development cost is more likely to be around US$125
million per drug [41, 42]. Best estimates of development
costs for imatinib, for example, were between US$38
million and US$96 million [43]. By comparison, the glo-
bal sales for imatinib reached US$4.69 billion or US$390
million per month in 2013 [44]. Moreover, the annual
cost of imatinib was US$30,000 per patient per year in
2001 in the US when it received FDA approval, a price
set by the company to make it profitable, and then
nearly tripled to US$90,000 in 2013, despite imatinib
having received additional indications, and being taken
by a higher number of patients for longer periods of
time than anticipated [22, 45]. In Australia, there was
enormous controversy recently when the funding for a
new treatment for advanced melanoma, ipulimumab
(Yervoy®) was rejected by the PBAC on two occasions
because the manufacturer, Bristol Myers Squibb, re-
quested a high price even if this medicine had a low re-
sponse rate and could cause severe immunological
adverse effects [46]. Despite the fact that development of
Yervoy® may have cost less than US$400 million [47],
Wall Street analysts expected Yervoy® to make US$1.7
billion a year in revenues when approved by FDA in
2011 [47].
In the UK, Professor David Haslam, the chairman of
the National Institute for Health and Care Excellence
(NICE), which is responsible for appraising the cost-
effectiveness of medicines in England, recently declared
that ‘The pharmaceutical industry must be willing to
show the public how it prices its drugs—or face losing its
trust…If we could have greater transparency about pri-
cing, then a lot of problems could be bypassed—it’s not
just that drugs are expensive and NICE says no, it’s
about the cost-effectiveness of these medicines’ [48]. In
the United States, a group of more than 100 experts in
chronic myeloid leukemia (CML), has recently drawn at-
tention to the high prices of cancer drugs [22]. American
oncologists have declared that ‘we cannot continue to
accept novel therapeutics with very small benefits for
exorbitant prices’ [49]. In France, independent experts
have claimed that ‘skyrocketing prices for new drugs call
for a strong response from citizens, healthcare profes-
sionals and health authorities’ [50]. The World Health
Organization Director General Margaret Chan recently
decried the astronomical costs of new medicines and
asked what was a fair profit for a pharmaceutical com-
pany [51].
Given that affordability is such a major issue when it
comes to access to high cost cancer medicines, refine-
ments of health technology assessment will, on their
own, be insufficient to address the problem of access to
cancer medicines in Australia. High prices of cancer
medicines are an international problem which require
global solutions. Greater transparency of medicine prices
and price-setting mechanisms, a greater commitment of
funding agencies—particularly US insurers—to value-
based pricing schemes, and greater awareness of pricing
issues among stakeholders including media, consumer
and health professional organisations might all help to
promote new business models in which the prices of
cancer medicines would reflect actual improvements in
health outcomes rather than solely what companies be-
lieve the market will bear.
Conclusions
Australia has implemented rigorous methods to promote
access to new medicines, including cancer medicines,
while also supporting the equity and the sustainability of
its universal pharmaceutical coverage scheme. Decisions
about the registration and funding of cancer medicines
are often challenging because of insufficient evidence of
benefits, and high prices requested by pharmaceutical
companies. A number of initiatives may improve and
streamline current administrative processes. The devel-
opment of managed entry programs may also help
maintain efficacy and cost-effectiveness standards while
meeting public’s expectations but the results of these
programs has not yet been evaluated. Better involvement
of public and patients in decision-making processes may
increase the legitimacy and the acceptability of funding
decisions. However, greater transparency concerning the
rationale and evidence base supporting reimbursement
decisions and the basis for the high prices requested by
pharmaceutical companies are still required to inform
and enhance public debate.
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